Ponatinib
A Bcr-Abl tyrosine kinase inhibitor.
General information
Ponatinib is a receptor tyrosine kinase inhibitor. It has potential antiangiogenic and antineoplastic activities (NCIt). Ponatinib was shown to potently inhibit SARS-CoV-2-mediated cytokine release in vitro (Chan et al., 2021).
Ponatinib on PubChem
Ponatinib on DrugBank
Ponatinib on Wikipedia
Marketed as
ICLUSIG
CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Small molecule |
in silico | 42.78 | Apr/30/2020 | |
|
Molecular Features of Non-Selective Small Molecule Antagonists of the Bradykinin Receptors
Small molecule In silico |
in silico | 4.29 | Predicted to non-selectively bind bradykinin receptors, which was theorised to alleviate SARS-CoV-2-related inflammation. |
Sep/21/2020 |
|
Machine learning identifies molecular regulators and therapeutics for targeting SARS-CoV2-induced cytokine release
Spike protein Spike variant Small molecule In vitro Mechanism In silico Al |
THP1 cells-derived macrophages | 11.43 | SARS-CoV-2 (WT/alpha/beta/delta variant) Spike protein’s N-terminal domain induced inflammation in an in vitro model. This inflammation was effectively inhibited by the compound. |
Sep/06/2021 |
